These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 15270789

  • 1. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M, GLAC Study Group.
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [Abstract] [Full Text] [Related]

  • 2. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y, DeFronzo RA.
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [Abstract] [Full Text] [Related]

  • 3. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 4. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET Study Group.
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [Abstract] [Full Text] [Related]

  • 5. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
    Derosa G, Cicero AF, Fogari E, D'Angelo A, Bianchi L, Maffioli P.
    Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S, Pioglitazone 014 Study Group.
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [Abstract] [Full Text] [Related]

  • 7. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 8. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.
    Parhofer KG, Otto C, Geiss HC, Laubach E, Göke B.
    Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):49-52. PubMed ID: 15662596
    [Abstract] [Full Text] [Related]

  • 9. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study.
    Davidson JA, Perez A, Zhang J, Pioglitazone 343 Study Group.
    Diabetes Obes Metab; 2006 Mar; 8(2):164-74. PubMed ID: 16448520
    [Abstract] [Full Text] [Related]

  • 10. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S, Prange A, Schulze J, Lettis S, Barnett AH.
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [Abstract] [Full Text] [Related]

  • 11. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
    Sharma PK, Bhansali A, Sialy R, Malhotra S, Pandhi P.
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
    [Abstract] [Full Text] [Related]

  • 12. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone.
    Cooper MB, Al Majali K, Bailey CJ, Betteridge DJ.
    Clin Endocrinol (Oxf); 2008 May; 68(5):738-46. PubMed ID: 17980009
    [Abstract] [Full Text] [Related]

  • 13. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 14. Effects of pioglitazone on lipid and lipoprotein metabolism.
    Betteridge DJ.
    Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
    [Abstract] [Full Text] [Related]

  • 15. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
    Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S.
    Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
    [Abstract] [Full Text] [Related]

  • 18. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
    Wallace TM, Levy JC, Matthews DR.
    Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
    [Abstract] [Full Text] [Related]

  • 19. Effects of a gel forming dietary fiber, guar gum, on the absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes.
    Uusitupa M, Södervik H, Silvasti M, Karttunen P.
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):153-7. PubMed ID: 2110937
    [Abstract] [Full Text] [Related]

  • 20. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
    Lester JW, Fernandes AW.
    Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.